Purpose: loss is frequent in gastrointestinal stromal tumors (GISTs) and associated with aggressive outcome. Palbociclib is a CDK4 inhibitor with preclinical antitumor efficacy in tumors with P16/CDKN2A loss.
Patients And Methods: This is a multicenter single-arm phase II clinical trial assessing safety and efficacy of palbociclib in patients with advanced GIST bearing gene loss. Adults with unresectable locally advanced or metastatic, refractory to at least imatinib and sunitinib, measurable and documented progressive disease (PD) as per RECIST 1.1, and deletion centrally assessed were eligible. Patients received palbociclib 125 mg orally daily on a 21 days on/7 days off dosing schedule, until PD or unacceptable toxicity. The primary endpoint was 4-month non-PD rate according to RECIST 1.1.
Results: As of May 2017, 71 patients had been included in the study, and 29 patients (40.3%) met the molecular eligibility requirement. Twenty-five patients (86.2%) had grade 1-2 adverse events (AEs) and 12 patients (41.4%) grade 3-4 AEs possibly related to the drug. The planned interim statistical analysis performed after central histologic and radiological review showed that 19 (86.4%) out of the first 22 evaluable patients had PD at 4 months. status had no impact either on overall survival or outcome on previous standard lines of treatment. Translational analysis suggested upregulation of or downregulation of or as potential mechanisms of resistance.
Conclusions: Palbociclib has no significant clinical activity as a single agent in deleted GIST refractory to imatinib and sunitinib.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-18-3127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of B7-H3 and B7-H4 in Gastric Gastrointestinal Stromal Tumors.
Appl Immunohistochem Mol Morphol
November 2024
University of Yamanashi, Chuo, Yamanashi, Japan.
Article Synopsis
- - Gastric gastrointestinal stromal tumors (GISTs) are tumors in the GI tract that originate from specific cells, and their treatment has significantly improved with imatinib, a drug that targets a specific protein called KIT, but many patients eventually see their disease progress.
- - There's a need for new treatment methods for GISTs that no longer respond to imatinib, as most patients face progression of their disease within a few years of treatment.
- - This study focuses on the role of immune checkpoint proteins B7-H3 and B7-H4 in gastric GISTs, finding that B7-H3 is expressed in nearly all GIST samples examined, indicating it may help tumors evade the immune system.
Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia.
J Med Cases
October 2024
Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Article Synopsis
- * A case study details a 75-year-old Hispanic male with relapsed/refractory Philadelphia-positive B-cell ALL, who was treated with multiple TKIs and chemotherapy, culminating in a novel combination of ponatinib and asciminib before and after brexu-cel therapy.
- * This combination of ponatinib and asciminib proved to be effective, controlling the disease for 2 months before brexu
CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.
Ann Hematol
November 2024
Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, 91054, Erlangen, Germany.
Chronic myeloid leukemia presenting de novo in the blast phase (CML-BP) is a rare diagnosis among pediatric malignancies. We report on a 16-year-old male who presented with CML-BP lymphoid at diagnosis. He was treated with shortened acute lymphoblastic leukemia induction plus the tyrosine kinase inhibitor (TKI) imatinib followed by dasatinib.
View Article and Find Full Text PDFA Challenging Case of Idiopathic Hypereosinophilic Syndrome: An Itching in the Brain.
Cureus
August 2024
Department of Cardiology, All India Institute of Medical Sciences, Nagpur, Nagpur, IND.
Article Synopsis
- Hypereosinophilia (HE) can be challenging to treat, especially when symptoms persist despite low eosinophil counts, necessitating thorough lab testing to uncover potential causes.
- A case study details a 58-year-old woman with diabetes and hypothyroidism who experienced severe itching and skin lesions, initially linked to pyelonephritis, and presented with elevated eosinophil levels resistant to conventional treatments.
- Following extensive mutation studies and a high bone marrow eosinophil count, the patient was successfully treated with imatinib, leading to normalization of eosinophil levels and symptom resolution over the next 1 to 1.5 years.
Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).
J Cancer Res Ther
April 2024
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Introduction: We conducted an open-label, single-arm, multi-center phase II trial to evaluate the efficacy and safety of imatinib chemotherapy-refractory or metastatic solid tumor patients with c-KIT mutations and/or amplification.
Methods: c-KIT mutations and amplification were detected using NGS. Imatinib (400 mg daily) was administered continuously in 28-day cycles until disease progression, unacceptable adverse events, or death by any cause.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!